Affordable Access

alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.

Authors
  • Capra, F1
  • Casaril, M
  • Gabrielli, G B
  • Tognella, P
  • Rizzi, A
  • Dolci, L
  • Colombari, R
  • Mezzelani, P
  • Corrocher, R
  • De Sandre, G
  • 1 Istituto di Clinica Medica, dell'Università di Verona, Italy.
Type
Published Article
Journal
Journal of Hepatology
Publisher
Elsevier
Publication Date
April 1993
Volume
18
Issue
1
Pages
112–118
Identifiers
PMID: 8340603
Source
Medline
License
Unknown

Abstract

Forty patients with chronic viral hepatitis or active cirrhosis (33 anti-HCV positive) entered a recombinant human alpha 2A interferon randomized trial. Twenty-one subjects were treated with 6 million units (MU) three times per week for 6 months. Nineteen were not treated. Six months later in 12 patients of the treated group (60% of the evaluable 20) with normalized serum aminotransferases levels (responders), fibrogenesis serum markers (NPIIIP and laminin) were significantly lower than baseline. In the untreated patients and in non-responders NPIIIP and laminin were unchanged. Semi quantitative histological evaluation (allotting scores for inflammation, necrosis and fibrosis) confirmed a significant improvement of necro-inflammation in the responders. These data suggest that alpha-IFN treatment may decrease stimuli for fibrogenesis by reducing liver inflammation and necrosis, thus preventing evolution to cirrhosis.

Report this publication

Statistics

Seen <100 times